Begin main content


Last Updated: August 8, 2019
Result type: Reports
Project Number: SR0626-000
Product Line: Common Drug Review

Generic Name: glucagon

Brand Name: TBC

Manufacturer: Eli Lilly Canada Inc.

Indications: Severe hypoglycemic reactions

Manufacturer Requested Reimbursement Criteria1: For the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated adult and pediatric patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.

Submission Type: New

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedJune 25, 2019
Patient group input closedAugust 15, 2019
Patient input summary sent for review to patient input groups-
Patient group comments on input summary closed-
Submission receivedJuly 24, 2019
Submission accepted for reviewAugust 08, 2019
Review initiatedAugust 09, 2019
Draft CADTH review report(s) sent to applicantOctober 24, 2019
Comments from applicant on draft CADTH review report(s) receivedNovember 04, 2019
CADTH review team's comments on draft CADTH review report(s) sent to applicantNovember 29, 2019
Canadian Drug Expert Committee (CDEC) meetingDecember 11, 2019
CDEC recommendation sent to applicant and drug plansDecember 23, 2019
January 02, 2020